Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups

Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America